(1.26%) 5 127.79 points
(1.18%) 38 676 points
(1.99%) 16 156 points
(-1.22%) $77.99
(5.65%) $2.15
(0.02%) $2 310.10
(-0.16%) $26.79
(0.37%) $966.20
(-0.35%) $0.929
(-1.07%) $10.87
(-0.11%) $0.797
(0.35%) $91.45
5 days till quarter result
(bmo 2024-05-09)
Expected move: +/- 14.57%
Live Chart Being Loaded With Signals
RVL Pharmaceuticals plc, a specialty pharmaceutical company, focuses on the development and commercialization of pharmaceutical products that target markets with underserved patient populations in the ocular and medical aesthetics therapeutic areas in the United States, Argentina, and Hungary...
Stats | |
---|---|
今日成交量 | 63.96M |
平均成交量 | 24.42M |
市值 | 3.14M |
EPS | $0 ( 2024-03-18 ) |
下一个收益日期 | ( $0 ) 2024-05-09 |
Last Dividend | $0 ( N/A ) |
Next Dividend | $0 ( N/A ) |
P/E | -0.0397 |
ATR14 | $0.0230 (500.00%) |
Date | Person | Action | Amount | type |
---|---|---|---|---|
2023-10-19 | Harsaul Foundation | Sell | 9 363 760 | Ordinary Shares |
2023-10-20 | Harsaul Foundation | Sell | 4 758 899 | Ordinary Shares |
2023-10-19 | Altchem Ltd | Sell | 9 363 760 | Ordinary Shares |
2023-10-20 | Altchem Ltd | Sell | 4 758 899 | Ordinary Shares |
2023-10-18 | Harsaul Foundation | Sell | 3 421 537 | Ordinary Shares |
INSIDER POWER |
---|
-78.39 |
Last 95 transactions |
Buy: 43 304 967 | Sell: 77 056 281 |
音量 相关性
RVL Pharmaceuticals plc 相关性 - 货币/商品
RVL Pharmaceuticals plc 财务报表
Annual | 2022 |
营收: | $49.72M |
毛利润: | $40.27M (80.98 %) |
EPS: | $-0.580 |
FY | 2022 |
营收: | $49.72M |
毛利润: | $40.27M (80.98 %) |
EPS: | $-0.580 |
FY | 2021 |
营收: | $17.50M |
毛利润: | $13.88M (79.33 %) |
EPS: | $-0.960 |
FY | 2020 |
营收: | $177.88M |
毛利润: | $103.40M (58.13 %) |
EPS: | $-1.310 |
Financial Reports:
No articles found.
RVL Pharmaceuticals plc
RVL Pharmaceuticals plc, a specialty pharmaceutical company, focuses on the development and commercialization of pharmaceutical products that target markets with underserved patient populations in the ocular and medical aesthetics therapeutic areas in the United States, Argentina, and Hungary. The company is commercializing Upneeq (RVL-1201), an oxymetazoline hydrochloride ophthalmic solution, for the treatment of acquired blepharoptosis, or low-lying eyelid in adults. The company was formerly known as Osmotica Pharmaceuticals plc and changed its name to RVL Pharmaceuticals plc in January 2022. RVL Pharmaceuticals plc is headquartered in Bridgewater, New Jersey.
关于 实时信号
此页面上呈现的实时信号有助于确定何时购买或出售NA. 信号具有高达1分钟的延迟;与所有市场信号一样,存在误差或错误的可能性。
实时交易信号不是绝对的,getagraph.com 对基于这些信号采取的任何行动概不负责,如《使用条款》中所述。这些信号是基于广泛的技术分析指标。